Neonatal outcomes of live births after blastocyst biopsy in preimplantation genetic testing cycles: a follow-up of 1,721 children
Blastocyst biopsy may not add additional risk to neonatal outcomes when compared with controls.
Volume 112, Issue 1, Pages 82–88
Hui He, M.D., Shuang Jing, M.Sc., Chang Fu Lu, Ph.D., Yue Qiu Tan, Ph.D., Ke Li Luo, Ph.D., Shuo Ping Zhang, Ph.D., Fei Gong, M.D., Ph.D., Guang Xiu Lu, M.D., Ge Lin, M.D., Ph.D.
To investigate whether blastocyst biopsy in preimplantation genetic testing (PGT) increases the risk of adverse neonatal outcomes.
Retrospective cohort study.
Live births after blastocyst biopsy combined with frozen ET (PGT group) and frozen blastocyst transfer after in vitro fertilization or intracytoplasmic sperm injection (control group).
Main Outcome Measure(s)
Gestational age (GA), birth weight (BW), and rates of preterm birth (PB), very preterm birth (VPB), extreme preterm birth (EPB), low birth weight (LBW), very low birth weight (VLBW), and macrosomia.
No significant differences were observed in the sex ratio, GA, PB, VPB, EPB, BW, or rates of LBW, VLBW, and macrosomia between the PGT and control groups for either singletons or twins. However, the cesarean section rate of the PGT group was significantly higher than that of the control group for twins (adjusted odds ratio, 2.383 [1.079, 5.259]). Regarding fluorescence in situ hybridization–PGT neonates, neonatal outcomes, including GA, BW, and rates of PB, VPB, LBW, and VLBW, did not differ between the different groups of biopsied cells (≥10 group and <10 group) for either the grade B or grade C trophectoderm score subgroups; however, in the grade B trophectoderm score subgroup, the rate of boy babies in the ≥10 group was significantly higher than that in the <10 group (83.3% vs. 40.9%). The association between the number of biopsied cells and GA/BW was not statistically significant.
Blastocyst biopsy may not add additional risk to neonatal outcomes when compared with a control group.